Nisa Investment Advisors LLC Boosts Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Nisa Investment Advisors LLC increased its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 11.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 940 shares of the company’s stock after purchasing an additional 94 shares during the period. Nisa Investment Advisors LLC’s holdings in Krystal Biotech were worth $173,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Jamison Private Wealth Management Inc. bought a new position in shares of Krystal Biotech in the second quarter worth approximately $28,000. GAMMA Investing LLC lifted its position in Krystal Biotech by 160.3% in the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after acquiring an additional 93 shares in the last quarter. Blue Trust Inc. lifted its position in Krystal Biotech by 2,328.6% in the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after acquiring an additional 163 shares in the last quarter. Quest Partners LLC purchased a new stake in Krystal Biotech during the 4th quarter valued at $127,000. Finally, Pier 88 Investment Partners LLC bought a new stake in shares of Krystal Biotech in the 4th quarter worth $145,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the transaction, the insider now owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 14.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms recently commented on KRYS. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Krystal Biotech in a research report on Monday, August 5th. Evercore ISI lifted their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research note on Monday, August 12th. Citigroup restated a “neutral” rating and set a $204.00 price objective (up previously from $195.00) on shares of Krystal Biotech in a research report on Tuesday, August 6th. Finally, Chardan Capital lifted their target price on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Krystal Biotech presently has an average rating of “Moderate Buy” and a consensus price target of $187.89.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $201.58 on Friday. The stock has a market capitalization of $5.76 billion, a PE ratio of 107.80 and a beta of 0.84. Krystal Biotech, Inc. has a 1-year low of $93.95 and a 1-year high of $219.34. The company’s fifty day simple moving average is $191.57 and its 200-day simple moving average is $170.80.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.03. The company had revenue of $70.28 million for the quarter, compared to the consensus estimate of $65.27 million. During the same period in the prior year, the firm posted ($1.25) EPS. The business’s revenue for the quarter was up 70283900.0% on a year-over-year basis. As a group, research analysts anticipate that Krystal Biotech, Inc. will post 2 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).